YTHDC1通过KMT2C-H3K4me1/me3表观遗传轴减弱DNA损伤应答,是B细胞急性淋巴细胞白血病的治疗靶点
本研究显示YTHDC1在B-ALL细胞中高表达,敲低YTHDC1可抑制B-ALL细胞体外增殖和细胞周期进展,并在人B-ALL异种移植模型中延长小鼠生存。机制上YTHDC1结合并稳定m6A修饰的KMT2C mRNA,促进H3K4甲基化及DNA损伤应答相关基因表达;YTHDC1抑制剂EPZ-5676与阿糖胞苷联用可提高B-ALL小鼠模型的化疗疗效。
要点
- YTHDC1在B-ALL细胞中高表达,敲低后抑制增殖和细胞周期进展。
- YTHDC1通过稳定m6A修饰的KMT2C mRNA上调H3K4甲基化及DNA损伤应答基因。
- EPZ-5676联合阿糖胞苷在YTHDC1高表达B-ALL小鼠模型中提高化疗疗效。
核心结论
- YTHDC1通过稳定m6A修饰的KMT2C mRNA上调DNA损伤应答相关基因表达,是B-ALL细胞DNA损伤应答所必需,靶向抑制YTHDC1是潜在的新型B-ALL治疗策略,尤其针对YTHDC1高表达B-ALL。
研究设计与样本
- 研究采用B-ALL细胞体外实验、人B-ALL异种移植小鼠模型、分子对接与生化实验,鉴定EPZ-5676为YTHDC1抑制剂并在YTHDC1高表达原代和细胞系B-ALL小鼠模型中评估其与阿糖胞苷联用。
主要发现
- YTHDC1在B-ALL细胞中高表达,敲低YTHDC1体外减弱B-ALL细胞增殖和细胞周期进展。
- 敲低YTHDC1在人B-ALL异种移植模型中延长小鼠生存,归因于白血病发生受损。
- 敲低YTHDC1显著增加B-ALL细胞内源性及化疗药物诱导的DNA损伤积累。
- YTHDC1结合并稳定m6A修饰的KMT2C mRNA,KMT2C催化H3K4甲基化以表达DNA损伤应答相关基因。
- EPZ-5676与阿糖胞苷联用在使用YTHDC1高表达原代和细胞系B-ALL细胞的小鼠模型中显著提高化疗疗效。
临床怎么用
- 作者认为靶向抑制YTHDC1是潜在的新型B-ALL治疗策略,尤其针对YTHDC1高表达B-ALL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive malignancy characterized by the aberrant accumulation of immature and dysfunctional B cells in bone marrow (BM). Although chemotherapy and other therapies have been widely applied, some patients such as relapsed or drug-refractory (R/R) B-ALL patients exhibit limited response. YT521-B homologous domain-containing protein 1 (YTHDC1) is a nuclear reader of N6-methyladenosine (m6A) RNA modification, which has been implicated in different malignancies including leukemia. In the current study, we show that YTHDC1 is highly expressed in B-ALL cells. YTHDC1 knockdown attenuated B-ALL cell proliferation and cell cycle progression in vitro, and prolonged survival of mice in the human B-ALL xenograft model in vivo attributable to compromised leukemogenesis. Mechanistically, YTHDC1 knockdown significantly increased the accumulation of endogenous and chemotherapeutic agents-induced DNA damage in B-ALL cells. Furthermore, we identified that YTHDC1 binds to and stabilizes m6A-modified KMT2C mRNA. KMT2C is a key enzyme catalyzing histone H3K4 methylation required for the expression of DNA damage response (DDR)-related genes, implying that YTHDC1 inhibitors might improve chemotherapy by attenuating DDR via reducing KMT2C. Indeed, with molecular docking and biochemical experiments, we identified EPZ-5676 as a YTHDC1 inhibitor, and combination of EPZ-5676 with Cytarabine (Ara-c) significantly improved the efficacy of chemotherapy in B-ALL mouse models using YTHDC1high primary and lined B-ALL cells. Collectively, YTHDC1 is required for DDR in B-ALL cells by upregulating DDR-related gene expression via stabilizing m6A-modified KMT2C mRNA, thereby leading to increased histone H3K4 methylation, and targeted inhibition of YTHDC1 is a potentially new therapeutic strategy against B-ALL, especially YTHDC1high B-ALL.
引用
- Li X, Zheng M, Ma S, et al. YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis. Leukemia. 2024. PMID: 39501105. doi:10.1038/s41375-024-02451-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。